Skip to main content

Breast Cancer

Ausgabe 2/2023

Inhalt (16 Artikel)

Open Access Special Article

Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018

Keiichiro Tada, Hiraku Kumamaru, Hiroaki Miyata, Sota Asaga, Kotaro Iijima, Etsuyo Ogo, Takayuki Kadoya, Makoto Kubo, Yasuyuki Kojima, Kenta Tanakura, Kenji Tamura, Masayuki Nagahashi, Naoki Niikura, Naoki Hayashi, Minoru Miyashita, Masayuki Yoshida, Shinji Ohno, Shigeru Imoto, Hiromitsu Jinno

Open Access Review Article

Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients

Mohammed Tarek Hasan, Mohamed Hamouda, Mohammad. K. El khashab, Ahmed Bostamy Elsnhory, Abdullah Mohamed Elghamry, Obada Atef Hassan, Aya Mamdouh Fayoud, Abdelrahman H. Hafez, Mohammed Al-kafarna, Abdulrahman Ibrahim Hagrass, Randa Kamal Rabea, Mohamed Ibrahim Gbreel

Original Article

Dynamic changes in quality of life, psychological status, and body image in women who underwent a mastectomy as compared with breast reconstruction: an 8-year follow up

Sriyani Padmalatha Konara Mudiyanselage, Yi-Lin Wu, Shikha Kukreti, Chang-Chun Chen, Chia-Ni Lin, Yi-Tseng Tsai, Han-Chang Ku, Su-Ying Fang, Jung-Der Wang, Nai-Ying Ko

Original Article

Performance analysis of screening mammography in Asian women under 40 years

Mi-ri Kwon, Yoosoo Chang, Boyoung Park, Seungho Ryu, Shin Ho Kook

Original Article

A cost-consequences analysis of the SAFE trial: a comparative, effectiveness trial evaluating high- versus low-supervision of an exercise intervention for women with breast cancer

Jessica T. Watzek, Louisa G. Gordon, Carolina X. Sandler, Rosalind R. Spence, Dimitrios Vagenas, Christopher Pyke, Sandra C. Hayes

Original Article

High PPFIA1 expression promotes cancer survival by suppressing CD8+ T cells in breast cancer: drug discovery and machine learning approach

Jinah Chu, Kyueng-Whan Min, Dong-Hoon Kim, Byoung Kwan Son, Hyung Suk Kim, Un Suk Jung, Mi Jung Kwon, Sung-Im Do

Original Article

Predictors of persistent post-surgical pain intensity and interference at 1 year after breast cancer surgery: assessing central sensitization, central sensitivity symptoms, and psychological factors

Masahiro Manfuku, Tomohiko Nishigami, Akira Mibu, Hirofumi Yamashita, Ryota Imai, Hiroe Kanamori, Kazuhiro Sumiyoshi

Original Article

Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study

Terufumi Kawamoto, Naoto Shikama, Nobuki Imano, Hikaru Kubota, Takashi Kosugi, Shuhei Sekii, Hideyuki Harada, Kazunari Yamada, Yutaka Naoi, Kazunari Miyazawa, Yasuhiro Hirano, Yuki Wada, Ayako Tonari, Tetsuo Saito, Nobue Uchida, Norio Araki, Naoki Nakamura

Open Access Original Article

Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04)

Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih

Original Article

Physicians’ perception about the impact of breast reconstruction on patient prognosis: a survey in Japan

Rena Yamakado, Makoto Ishitobi, Naoto Kondo, Chikako Yamauchi, Shinsuke Sasada, Hiroko Nogi, Miho Saiga, Akiko Ogiya, Kazutaka Narui, Hirohito Seki, Naomi Nagura, Ayaka Shimo, Teruhisa Sakurai, Naoki Niikura, Hiroki Mori, Tadahiko Shien

Original Article

Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study

Tomoe Taji, Nina Odan, Yuki Kataoka, Mako Ikeda, Ai Yamaguchi, Eiji Suzuki, Hirofumi Suwa

Open Access Original Article

CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients

Caroline Bailleux, Antoine Arnaud, Jean-Sébastien Frenel, Sylvie Chabaud, Thomas Bachelot, Benoît You, Laëtitia Stefani, Claire Garnier Tixidre, Hélène Simon, Dominique Beal-Ardisson, Jean-Philippe Jacquin, Francesco Del Piano, Alain Lortholary, Claudiu Cornea, Charlotte Greilsamer, Rémy Largillier, Fabien Brocard, Eric Legouffe, Mustapha Atlassi, Anne-Claire Hardy-Bessard, Pierre-Etienne Heudel

Original Article

Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort

Laetitia Collet, Lauriane Eberst, Gauthier Ludovic, Marc Debled, Loana Hrab, Marie-Ange Mouret-Reynier, Isabelle Desmoulins, Anthony Goncalves, Mario Campone, Jean-Marc Ferrero, Etienne Brain, Lionel Uwer, Jean-Christophe Eymard, Veronique Dieras, Gaetane Simon, Marianne Leheurteur, Florence Dalenc, Laurence Vanlemmens, Amelie Darlix, Monica Arnedos, Thomas Bachelot

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.